Hitachi Chemical Co. America, Ltd. (San Jose, California), a subsidiary of Hitachi Chemical (Tokyo) has completed its purchase of the 80.1% remaining membership interest in PCT Cell Therapy Services (PCT, New Jersey) from Caladrius Biosciences.
Following the acquisition, PCT has become an independent business unit dedicated to cell therapy and regenerative medicine within the life sciences division of Hitachi Chemical.
Hitachi Chemical will leverage PCT’s extensive experience in cell therapy development and manufacturing technology, wide-ranging manufacturing locations, sales network and other resources to expand and strengthen services in the United States and add services in Japan, Europe, and other regions. In addition, PCT will be able to expand manufacturing capacity, capabilities, and service offerings.
“The acquisition of PCT marks an important milestone in the expansion of Hitachi Chemical’s regenerative medicine-related businesses,” says Hisashi Maruyama, CEO, Hitachi Chemical.
By Kartik Kohli
Source: Chemical Week
Chemical engineering researchers have developed a new catalyst that significantly increases yield in styrene manufacturing, while simultaneously reducing energy use and greenhouse gas emissions.
With efficiencies above 90%, Topsoe’s proprietary SOEC electrolyzers offer superior performance in electrolysis of water into hydrogen, when compared to today’s standard alkaline or PEM electrolyzers.
Chevron Phillips Chemical announced that Bruce Chinn, currently president, Chevron Chemicals, will become chief executive officer. B.J. Hebert, currently executive vice president and chief operating officer, will become president and chief operating officer.
